

1 **The prevalence of low dose aspirin use for prevention of adverse cardiovascular events**
2 **and its associated factors among patients with diabetes mellitus: A hospital based cross-**
3 **sectional study**

4
5 Kedir Negesso Tukeni^{1,*¶}, Ebrahim Umer Mohammed², Nigatu Asfaw Regassa³, Eyob Girma
6 Abera^{4, 5¶}

7
8
9 Author affiliations

10 ¹Department of Internal Medicine, Jimma University, Jimma, Oromia, Ethiopia

11 ²Department of Internal Medicine, Adama Hospital Medical College, Adama, Oromia, Ethiopia

12 ³Department of Internal Medicine, Mettu Carl Hospital, Oromia, Ethiopia

13 ⁴Department of Public Health, Jimma University, Jimma, Oromia, Ethiopia

14 ⁵Clinical Trial Unit, Jimma University, Jimma, Oromia, Ethiopia

15
16
17
18 *Corresponding author

19 Kedir Negesso Tukeni

20 Email: [kadiir2011@gmail](mailto:kadiir2011@gmail.com)

21
22 ¶These authors contributed equally to this work.

23 Abstract

24 **Background:** Cardiovascular diseases (CVD) are the most common causes of mortality and
25 morbidity among diabetic patients. Aspirin is recommended for primary and secondary
26 prevention of cardiovascular events in patients with diabetics who are eligible for therapy based
27 on active international guidelines. However, these active guidelines are underutilized. Hence,
28 this article helps to assess low dose aspirin use and its associated factors in patients with diabetes
29 mellitus on follow-up at the diabetes clinic of Jimma Medical Center (JMC).

30 **Method:** A cross-sectional study was conducted among 388 diabetic patients on follow-up at the
31 diabetic clinic of JMC during October 1, 2020 to November 15, 2020. The collected data were
32 cleaned and entered into EpiData version 4.6 then exported to STATA version 16.0 for analysis.
33 Descriptive statistics and multivariable logistic regression was employed to identify the
34 relationship between dependent and independent variables with declaring statistical significance
35 if P value is less than 0.05.

36 **Result:** Out of the total 388 diabetic patients interviewed, Most of the patients were in the age
37 group of 50-54 (35.8%) with the mean age of 48.8 [48.2, 51.4] years old. About half (48.7%) of
38 them had a history of hypertension. Nearly double of the study participants (47.2%) were
39 utilizing a low dose aspirin. Aspirin was indicated for 80 (20.6%) of the patients despite 21
40 (26.2%) of them were not using it. It was both indicated and prescribed in 59 (15.2%) of the
41 cases. Older age, longer duration of DM, dyslipidemia, and hypertension were associated with
42 more likely utilization of low dose aspirin.

43 **Conclusion:** About half of the DM patients were utilizing low dose aspirin, while only one fifth
44 of them were having indications to do so. Furthermore, one fourth of the patients were not
45 taking low dose aspirin for the prevention of cardiovascular events despite they were supposed
46 to use it. Therefore, these findings suggest a greater need for physicians to carefully assess the
47 indications to prescribe aspirin with a clear explanation of the it's advantages in these specific
48 patient population. Ultimately, future studies should examine the influence of updating
49 guidelines on clinician behaviors to avoid irrational use of aspirin and the association of
50 changing trends in preventive aspirin use with the development of CVD in patients with DM.

51

52 *Keywords: low dose Aspirin, Diabetes mellitus, Cardiovascular diseases, primary prevention,*
53 *secondary prevention*

54 **Introduction**

55 The burden of cardiovascular disease (CVD) is substantial in patients with diabetes mellitus
56 (DM), who have a two-to four-fold increase in the incidence of cardiovascular events compared
57 with age- and sex-matched, non-diabetic persons [1]. The prevalence of DM increased from 108
58 million (4.7%) in 1980 to 425 million (8.5%) in 2017, and it is estimated to be 629 million by
59 2045 [2]. Morbidity and mortality of CVD in patients with type 2 DM have a risk of death from
60 cardiovascular causes that is two to six times that among persons without DM, and among white
61 Americans the age-adjusted prevalence of coronary heart disease is twice as high among those
62 with type 2 DM as among those without DM [3]. Diabetes-related CVD complications are on the
63 rise that associated with cardiovascular risk factors. Coronary heart disease (CHD) may affect
64 5% to 8% of type 2 diabetic patients and cardiomyopathy, up to 50% of all patients. Close to
65 15% of patients with stroke have diabetes, and up to 5% of diabetic patients present with
66 cerebrovascular accidents at diagnosis [4].

67 In 2015, the Ethiopian Diabetes Association (EDA) and International Diabetic Federation (IDF)
68 reported almost the same number of people living with diabetes in the country 1.33 million and
69 1.30 million respectively [5]. Various studies were conducted to assess the prevalence of CVD in
70 patients with DM in Ethiopia. The overall prevalence of CVD among T2DM patients was
71 42.51% in Harari regional state of Ethiopia [6], 15.29% in Jimma Medical Center (JMC) [7]. A
72 systematic review conducted from institutional and community based studies with 5%
73 prevalence of CVD in patients with DM reported [8].

74 Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in
75 high-risk patients with previous myocardial infarction (MI) or stroke (secondary prevention) [9].
76 In the primary prevention trials, aspirin allocation yielded a 12% proportional reduction in
77 serious vascular events [10]. With its therapeutic dosage of 75–162 mg/day may be considered as
78 a primary prevention strategy in those with Type 1 or Type 2 diabetes who are at increased
79 cardiovascular risk [11]. However, its net benefit in primary prevention among patients with no
80 previous cardiovascular events is more controversial both for patients with diabetes and for
81 patients without diabetes [12]. An association between increases in aspirin dose and risk of
82 adverse events has been confirmed in multiple studies, whereas no such dose relationship has

83 been identified for efficacy. This suggests that following the rapid, acute inhibition of platelet
84 COX-1 with 160 to 325 mg of aspirin, every effort should be made to minimize the long-term
85 dosage [13]. Aspirin has been considered underutilized despite its beneficial effects in primary
86 and secondary prevention of CVD in patients with DM (14). Therefore, this paper assessed the
87 prevalence of low dose aspirin utilization and its associated factors in patients with DM at JMC.

88 **Methods**

89 **Study design and setting**

90 A cross-sectional study was conducted during October 1, 2020 to November 15, 2020 at the
91 diabetes clinic of JMC, which is located in Jimma town, Southwest Ethiopia, in Oromia region.
92 JMC is a tertiary teaching hospital located in Jimma Town serving a population of over 20
93 million.

94 **Source and study population**

95 All Type 1 and Type 2 diabetic patients on follow up at diabetes clinic of JMC from October 1,
96 2020 - November 15, 2020.

97 **Inclusion and exclusion criteria**

98 **Inclusion criteria**

99 All Type 1 and Type 2 diabetic patients on follow up at JMC diabetes clinic.

100 **Exclusion criteria**

101 All patients who deny verbal consent to the interview were excluded.

102 **Sample size determination and sampling technique**

103 The sample size was determined by using single population proportion formula, by considering
104 50% population proportion of aspirin users, 95% confidence level, 0.05 margin of error and by
105 considering 5% of expected non-response rate, the calculated total sample size was 403. A
106 convenient sampling technique was used taking consecutive patients who come for follow up
107 until the sample size is reached within the study period.

108 **Data collection instruments and procedure**

109 To assess the prevalence of aspirin use and its associated factors in patients with DM, a
110 structured data collection format was used including the socio-demographic characteristics (age,
111 sex, chart number, marital status, level of education, monthly income, and area of residence) and
112 clinical profiles such as duration of DM, history of CVD and co-administered medications. Prior
113 to data collection, the questionnaire was tested for consistency. The charts of the study

114 population were collected and reviewed after cross-checking chart number on the chart with that
115 on the registration book. Additionally, patients were also interviewed to get the missed data from
116 the charts. Then the data were filled by the investigator into the questionnaire. The data
117 collectors were used personal protective equipment like alcohol-based hand sanitizer, and face
118 mask to reduce the risk of transmission of Corona virus disease (COVID-19) during data
119 collection.

120 **Operational Definition**

- 121 **I. Diabetes mellitus:** Refers to a group of common chronic metabolic disorders that
122 share the phenotype of hyperglycemia [14].
- 123 **II. Primary prevention:** Initiating appropriate interventions to decrease the likelihood of
124 the first cardiovascular disease occurrence [12].
- 125 **III. Secondary prevention:** Initiating the appropriate interventions after a patient suffered
126 an initial cardiovascular insult to minimize the possibility of further insults [12].
- 127 **IV. Dyslipidemia:** An abnormal serum concentration and /or abnormal modifications of
128 lipids in the body [12].
- 129 **V. Low dose aspirin:** A dose of aspirin in the range of 75- 162 mg [12].
- 130 **VI. ASCVD score:** Is a score with different components being used to predict the 10
131 years' likelihood of developing CVD [12].
- 132 **VII. Major Cardiovascular events:** composite of nonfatal stroke, non-fatal myocardial
133 infarction, and cardiovascular death [12].

134 **Data quality management**

135 All data were collected using a uniform data collection format, and all investigators were trained
136 with the standardized study protocol. The collected data was checked for completeness and
137 consistency on each day of collection. The principal investigator led the overall activities during
138 the data collection period. Questionnaires were prepared in English and back-translated into
139 Afan Oromo/Amharic and translated back into English to check its consistency. The Afan
140 Oromo/Amharic versions were used for data collection after pretesting on 5% of the actual
141 sample size before the data collection. Amendments were made accordingly after pre-testing.
142 Both chart review and patient interview were conducted under strict supervision.

143 **Data processing and analysis**

144 Data were entered, coded, and cleaned in EpiData manager version 4.6 and then exported to
145 STATA version 16.0 for analysis. Summary findings were presented by tables. Descriptive
146 statistics were used to determine the demographic characteristics and pattern of aspirin
147 utilization. The potential predictor variables were tested in bi-variable logistic regression
148 separately for their association with aspirin utilization. The variables which are significant in the
149 bi-variable analysis at a cut point of P-value of < 0.25 were a candidate for multi-variable
150 logistic regression analysis. Finally, a p-value < 0.05 will be used as a cut-off point for the
151 presence of statistical significance.

152 **Ethical approval**

153 Ethical clearance was obtained from the Ethical Review Board of Jimma University with a
154 permission obtained from the medical center. Written informed consent from the study
155 participants was obtained and patient confidentiality was ensured during the study period.

156 **Result**

157 Out of 403 eligible participants, a total of 388 diabetic patients were interviewed for this study as
158 15 patients were discontinued the interview, yielding a response rate of 96.3%.

159 **Socio-demographic characteristics**

160 Most of the patients were in the age group of 50-54 (35.8%) with the mean age of 48.8 [48.2,
161 51.4] years old. The majority of the patients were male (69.1%), and more than half patients
162 were from the rural side of Jimma, Ethiopia (Table 1).

163 Table 1: Socio-demographic characteristics of diabetic patients on follow up at JMC
164 diabetic clinic, Southwest Ethiopia, in 2020.

Variable	Categories	Frequency (n=388)	Percentage
Age	<=29	55	14.2
	30-39	37	9.5
	40-49	80	20.6
	50-64	139	35.8
	>=65	77	19.8
Sex	Male	268	69.1
	Female	120	30.9
Marital status	Married	331	85.3
	Single	35	9.1
	Divorced	10	2.5
	Widowed	12	3.1
Educational status	Never attended school	111	28.6
	Primary school	165	42.5
	Secondary school	58	14.9
	College and above	54	13.9
Residence	Urban	179	46.1
	Rural	209	53.9
Monthly Income (ETB)	<500	17	4.4
	500-1500	61	15.7
	1501-3000	60	15.5
	3001-5000	86	22.2
	>=5001	164	42.3

165 **Clinical characteristics**

166 Of the total participants, majority of the patients were having 5-9 years history of DM (30.9%),

167 nearly half (48.7%) patients had a history of hypertension. Among the 388 assessed patients, 27
 168 (6.9%) patients were with the history of heart attack, ischemic stroke or peripheral arterial disease
 169 (Table 2).

170 Table 2: Clinical characteristics of diabetic patients on follow-up at JMC diabetic clinic,
 171 Southwest Ethiopia, in 2020

Variable	Categories	Frequency	Percentage
Duration of DM (years)	< =1	60	15.5
	2-4	91	23.5
	5-9	120	30.9
	10-14	63	16.2
	>=15	54	13.9
History of hypertension	Yes	189	48.7
	No	199	51.3
Current smoker	Yes	6	1.5
	No	382	98.5
Dyslipidemia	Yes	110	30.1
	No	278	69.9
CKD*/albuminuria	Yes	27	7.4
	No	361	92.6
History of heart attack, ischemic stroke or peripheral arterial disease	Yes	27	6.9
	No	361	93.1
Type of heart disease (n=27)	Myocardial infarction	7	25.9
	Ischemic stroke	17	62.9
	Peripheral arterial disease	3	11.2

172 CKD*, Chronic kidney disease

173 **Prevalence of low dose aspirin use among diabetics on follow up**

174
 175 Nearly half of patients with DM, 183 (47.2%) were utilizing low dose of aspirin (Fig1).

176 **Figure 1: Magnitude of low dose aspirin use among DM patients on follow up**

177 **Pattern of use of low dose aspirin among diabetics on follow up**

178 The largest proportions (24.2%) of participants taking low dose aspirin were in the age group of
 179 50-64 years old. One hundred thirty-six male participants reported they were taking low dose
 180 aspirin. Most of patients (32.2%) with the history of hypertension were using aspirin (Table 3).

181 Table 3: Pattern of use of low dose aspirin use among diabetics on follow up at JimmaMedical
 182 Center diabetic clinic, Southwest Ethiopia, in 2020

Variables	Categories	Have you been taking low dose aspirin	
		Yes(%)	No (%)
Age group	<=29	5 (1.3)	50 (12.9)
	30-39	4 (1.0)	33 (8.5)
	40-49	24 (6.2)	56 (14.4)
	50-64	94 (24.2)	45 (11.6)
	>=65	56 (14.4)	21 (5.4)
Sex	Male	136 (35.1)	132 (34.0)
	Female	47 (12.1)	73 (18.8)
Education	Never attended school	59 (15.2)	52 (13.4)
	Primary school	71 (18.1)	94 (24.2)
	Secondary school	23 (5.9)	35 (9.0)
	College and above	30 (7.7)	24 (6.2)
Residence	Urban	96 (24.7)	83 (21.4)
	Rural	87 (22.5)	122 (31.4)
Monthly Income (ETB)	<500	5 (1.3)	12 (3.1)
	500-1500	32 (8.3)	29 (7.5)
	15001-3000	27 (6.9)	33 (8.5)
	3001-5000	51 (13.1)	35 (9.0)
	>=5001	68 (17.5)	96 (24.7)
Duration of DM (years)	<=1	13 (3.4)	47 (12.1)
	2-4	33 (8.5)	58 (14.9)
	5-9	72 (18.6)	48 (12.4)
	10-14	36 (9.3)	27 (6.9)
	>=15	29 (7.5)	25 (6.4)
History of hypertension	Yes	125 (32.2)	64 (16.5)
	No	58 (14.9)	141 (36.3)

183 **Primary and secondary prevention of DM and low dose aspirin use**

184 Among 388 DM patients, 80 (20.6%) of them had an indication to use a low dose aspirin while
 185 53 (13.7%) patients were with a primary indications. However, only 59 (73.8%) of patients were
 186 using it, and from those who were using aspirin out of 183 patients, 103 (56.3%) were
 187 inappropriately using aspirin. Out of the 27 DM patients who have had an indication to receive
 188 low dose aspirin as a secondary prevention, seven (25.9 %) of them were not taking even if they
 189 were supposed to use it (Table 4).

190 Table 4: Clients adherence to ADA 2020 guidelines to use low dose aspirin

Variables	Categories	Taking low dose aspirin		Chi square	P-value
		Yes	No		
Primary prevention indicated	Yes	39 (10.1%)	14 (3.6%)	17.194	0.000*
	No	144 (37.1)	191 (49.2)		
Secondary prevention indicated	Yes	20 (5.2%)	7 (1.8%)	8.432	0.004*
	No	163 (42.0%)	198 (51.0%)		

191 *P value** <0.05 shows statistical significance

192 **Reasons for not using low dose aspirin use in indicated cases**

193 Among 80 DM patients with having an indication to use aspirin, 21 (26.2%) clients were not using
 194 aspirin, the most(55.2%) commonly cited reason for not using low dose aspirin were being not
 195 prescribed (**Fig 2**).

196 **Figure 2: Reason for not using low dose aspirin in indicated case in patients with DM**

197 **Factors associated with low dose use of aspirin among diabetics**

198 After controlling confounding effects using multivariable logistic regression, factors influencing
 199 the use of aspirin among patients with DM were the duration of DM, age group, dyslipidemia,
 200 history of hypertension, and chronic kidney disease/albuminuria. Patients who live 10-14 years
 201 with DM were six times more likely [AOR 6.25 (95% C.I. 2.33, 16.75)] utilized a low dose
 202 aspirin as compared to those living with DM for less than 2 years. In terms of age group, those in
 203 the age group of 40-49 years, 50-64 years, and 65 years above were 3.99, 7.28, and 8.51 more
 204 likely to utilize a low dose of aspirin as compared to those under 30 years of age respectively.
 205 Participants who have a history of hypertension were about twice more likely [AOR 1.97 (95%
 206 C.I 1.11, 3.50)] and those who have dyslipidemia were three times more likely [AOR 3.07 (95%
 207 C.I 1.60, 5.90)] to utilize a low dose of aspirin compared to their counterparts (Table 5).

208 Table 5: A multi-variable logistic regression model of low dose aspirin use among diabetics on
 209 follow up at JMC diabetic clinic, Southwest Ethiopia, in 2020

Variables	Category	Low dose aspirin					
		OR	Std. Err.	Z	P>z	[95% C.I]	
Duration of DM (years)	<=1	1.00	(base)				
	2-4	3.95	1.84	2.95	0.003*	1.59	9.82
	5-9	5.72	3.01	5.38	0.000*	3.04	8.09
	10-14	6.25	3.14	3.64	0.000*	2.33	16.75
	>=15	3.49	1.76	2.49	0.013*	1.30	9.35
Monthly Income (ETB)	<500	1.00	(base)				
	500-1500	2.41	1.91	1.11	0.267	0.51	11.38
	15001-3000	2.18	1.72	0.99	0.322	0.47	10.21
	3001-5000	3.94	2.94	1.84	0.066	0.92	16.97
	>=50001	2.01	1.47	0.95	0.341	0.48	8.40
Age group	<30	1.00	(base)				
	30-39	1.15	0.85	0.19	0.849	0.27	4.86
	40-49	3.99	2.29	2.42	0.016*	1.30	12.28
	50-64	7.28	6.05	5.28	0.000*	4.22	9.72
	>64	8.51	7.65	5.14	0.000*	5.86	13.85
History of hypertension	Yes	1.97	0.58	2.30	0.021*	1.11	3.50
	No	1.00	(base)				
Dyslipidemia	Yes	3.07	1.02	3.37	0.001*	1.60	5.90
	No	1.00	(base)				
CKD ^a /albuminuria	Yes	1.00	(base)				
	No	1.01	0.43	0.03	0.978	0.44	2.31
Constant		0.03	0.04	-2.40	0.017	0.00	0.53

210 CKD^a, chronic kidney disease; *P value** < 0.05, statistical significance

211 **Discussion**

212 This thesis was conducted on 388 diabetic patients to assess the use of low dose aspirin and
213 associated factors for primary and secondary prevention of cardiovascular disease among
214 diabetic patient at JMC from September to November 2020. Of the 388 DM patients, 188 (47.2
215 %) of them use low dose aspirin. This is a higher rate than the findings in the analysis of the
216 National Health and Nutrition Examination Survey 2011–2012 conducted in the U.S. to examine
217 the use of aspirin for CVD prevention that showed 40.9% reported being told by their physician
218 to take aspirin, with 79.0% (31.6 %of the total) complying [15]. However, a study conducted in
219 US to assess the use of aspirin in diabetes and non-diabetes participants shows a higher use of
220 aspirin utilization among older adults (61.7%) than this study [16]. This is because of the study
221 conducted specifically among older patients with a higher risk rate of indications that possibly
222 increase the utilization of aspirin use. In china, aspirin utilization was 53.5% which is a higher
223 than this study [17].

224 Among the 27 DM patient with ASCVD, 20 (74.1%) were on low dose aspirin; which is
225 comparable with the study conducted in US to assess recent self-reported regular aspirin use
226 among adults 35 years or older with diabetes in 2001, 74.2 % [18]. From this study, 21.3% of
227 DM patients have had inappropriate aspirin use for primary prevention which is lower than the
228 study conducted in Turkey, 59.2% [19]. However, it was nearly doubled of the inappropriate
229 utilization of aspirin for primary prevention when compared with the study conducted in US which
230 was 11.6% [20]. As per ADA (American Diabetic Association) 2020 guideline [12], among the
231 388 DM patients, aspirin was indicated for 80 (20.6%) of the patients despite 21 (26.2%) of them
232 were not using it. It was both indicated and prescribed in 59 (15.2%) of the cases. This result is
233 higher when compared to the study conducted in Saudi Arabia, of 312 patients, aspirin was
234 indicated for 17.0% but it was not prescribed; it was both indicated and prescribed in 36.2% of
235 the cases [1]. When compared to the study conducted in India [21], 11% of patients were
236 prescribed with an indication for a primary prevention which is similar with this study,
237 10.6%; however, 10% of the patients were not utilized despite indicated for a primary
238 prevention which is higher than this study (3.6%) and there was no documentation for the
239 reasons not using aspirin while this study found that 55.2% of patients were reasoned “not

240 *prescribed*".

241 In this study, older age, longer duration of DM, dyslipidemia, hypertension, were associated with
242 more likely utilization of low dose aspirin. A similar study done in US, among both in low and
243 high-risk individuals for primary and secondary prevention, higher age groups were more likely
244 to utilize a low dose of aspirin as compared to their counterparts [AOR 5.29 (95% C.I. 3.64,
245 7.69)] [15] which is similar to this study as age group was found to be a significant predictor of
246 using a low dose of aspirin, which is nearly nine more likely to utilize a low dose of aspirin as
247 compared to those younger age groups [AOR 8.51 (95% C.I. 5.86, 13.85)]. The increase in the
248 prevalence of aspirin use in older populations with diabetes over recent decades may be due to a
249 multitude of factors. Before 2019, aspirin was recommended for older than 50 years without an
250 upper cutoff age limit [22]–[24]. With the updated guideline of the ADA in 2019, aspirin use was
251 discouraged for primary prevention in adults older than 70 years despite aspirin could be
252 considered for patients with high CVD risk and low bleeding risk [25]. In the same year, the
253 American College of Cardiology (ACC) and the American Heart Association (AHA) released
254 updated guidelines that recommended against routine aspirin use for primary prevention in adults
255 older than 70 years [26]. Duration of DM was significantly influencing low dose aspirin
256 utilization. This could be due to detection of risk factors as indications to use low dose aspirin
257 through time during follow-ups. Patients with a history of hypertension were about twice more
258 likely to utilize a low dose of aspirin compared to non-hypertensive DM patients. This is due to
259 its potential risk factor for CVD. As study showed the effect of aspirin in patients with
260 hypertension and diabetes mellitus, there was a 51% reduction in major cardiovascular events in target
261 group ≤ 80 mm Hg compared with target group ≤ 90 mm Hg (p for trend=0.005) [27].

262 **Study limitation**

263 The limitation of this study included that patients may not properly remember their age and this
264 may change the recommendations for use of aspirin as the indication for primary prevention of
265 ASCVD is dependent on age. Moreover, we used a cross-sectional study design and cannot draw
266 conclusions related to temporal use of low dose aspirin of any observed associations.

267 **Conclusion**

268 According to this study, almost half of the DM patients were utilizing low dose aspirin, while

269 only one fifth of them were having indications to do so. And hence more than half of the
270 patients were inappropriately using low dose aspirin. Furthermore, one fourth of the patients
271 were not taking low dose aspirin for the prevention of cardiovascular events despite they were
272 supposed to use it. Therefore, these findings suggest a greater need for physicians to carefully
273 assess the indications to prescribe aspirin with a clear explanation of the advantages of low dose
274 aspirin in these specific patient population. Ultimately, future studies should examine the
275 influence of updating guidelines on clinician behaviors to avoid irrational use of aspirin and the
276 association of changing trends in preventive aspirin use with the development of CVD in patients
277 with DM.

278 **Acknowledgement**

279 We would like to express our sincere and deep-rooted thanks to study participants and data
280 collectors for the support provided since the training upon the final submission of the
281 manuscript.

282 **Conflict of interest**

283 The authors report no conflicts of interest in this work.

284 **Funding**

285 This research received no specific grant from any funding agency in the public, commercial, or
286 not-for-profit sectors.

287 **Authors' contribution**

288 Conceptualization: KNT,NAR; Writing – original draft: KNT,NAR; Statistical analysis: EG;
289 Data Curation: NAR, EUM; Writing – review & editing: KNT, EGA

290 Reference

- 291 [1] B. A. Alkhail, R. Iftikhar, and A. Al Shaikh, "Use of Aspirin and Statin as primary
292 prevention for cardiovascular diseases," *Pakistan J. Med. Sci.*, vol. 32, no. 6, p. 1336,
293 2016.
- 294 [2] D. Glovaci, W. Fan, and N. D. Wong, "Epidemiology of diabetes mellitus and
295 cardiovascular disease," *Curr. Cardiol. Rep.*, vol. 21, pp. 1–8, 2019.
- 296 [3] W. Fan, "Epidemiology in diabetes mellitus and cardiovascular disease," *Cardiovasc.*
297 *Endocrinol.*, vol. 6, no. 1, p. 8, 2017.
- 298 [4] A. P. Kengne, A. G. B. Amoah, and J.-C. Mbanya, "Cardiovascular complications of
299 diabetes mellitus in sub-Saharan Africa," *Circulation*, vol. 112, no. 23, pp. 3592–3601,
300 2005.
- 301 [5] A. Zekewos, E. Loha, T. Egeno, K. Wubshet, and Z. Merga, "Prevalence of diabetes
302 mellitus and associated factors in Southern Ethiopia: a community based study," *Ethiop. J.*
303 *Health Sci.*, vol. 28, no. 4, 2018.
- 304 [6] L. D. Regassa, A. Tola, and Y. Ayele, "Prevalence of cardiovascular disease and
305 associated factors among type 2 diabetes patients in selected hospitals of Harari region,
306 eastern Ethiopia," *Front. Public Heal.*, vol. 8, p. 532719, 2021.
- 307 [7] G. R. Debele *et al.*, "Incidence and Predictors of Cardiovascular Disease among Type 1
308 and Type 2 Diabetes Mellitus in a Tertiary Health Care Setting of Ethiopia: 8-Year
309 Retrospective Follow-Up Study," *Risk Manag. Healthc. Policy*, pp. 1959–1968, 2021.
- 310 [8] D. A. Angaw, R. Ali, A. Tadele, and S. Shumet, "The prevalence of cardiovascular
311 disease in Ethiopia: a systematic review and meta-analysis of institutional and
312 community-based studies," *BMC Cardiovasc. Disord.*, vol. 21, no. 1, pp. 1–9, 2021.
- 313 [9] J. M. Guirguis-Blake, C. V Evans, C. A. Senger, E. A. O'Connor, and E. P. Whitlock,
314 "Aspirin for the primary prevention of cardiovascular events: a systematic evidence
315 review for the US Preventive Services Task Force," *Ann. Intern. Med.*, vol. 164, no. 12,
316 pp. 804–813, 2016.
- 317 [10] C. Baigent *et al.*, "Aspirin in the primary and secondary prevention of vascular disease:
318 collaborative meta-analysis of individual participant data from randomised trials.," *Lancet*,
319 vol. 373, no. 9678, pp. 1849–1860, 2009.
- 320 [11] M. Pignone *et al.*, "Aspirin for primary prevention of cardiovascular events in people with
321 diabetes: a position statement of the American Diabetes Association, a scientific statement
322 of the American Heart Association, and an expert consensus document of the American
323 College of Cardiology Foundation," *Circulation*, vol. 121, no. 24, pp. 2694–2701, 2010.
- 324 [12] D. Care, "Standards of medical care in diabetes-2020," *Diabetes Care*, vol. 43, pp. S1–
325 S224, 2020.
- 326 [13] G. De Berardis *et al.*, "Aspirin and Simvastatin Combination for Cardiovascular Events
327 Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy
328 of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes
329 mellitus treated with statins," *Trials*, vol. 8, no. 1, pp. 1–9, 2007.
- 330 [14] A. D. Association, "Diagnosis and classification of diabetes mellitus," *Diabetes Care*, vol.
331 33, no. Supplement_1, pp. S62–S69, 2010.
- 332 [15] A. G. Mainous III, R. J. Tanner, R. I. Shorr, and M. C. Limacher, "Use of aspirin for
333 primary and secondary cardiovascular disease prevention in the United States, 2011–

- 334 2012,” *J. Am. Heart Assoc.*, vol. 3, no. 4, p. e000989, 2014.
- 335 [16] E. Y. Liu, M. E. Al-Sofiani, H.-C. Yeh, J. B. Echouffo-Tcheugui, J. J. Joseph, and R. R.
336 Kalyani, “Use of preventive aspirin among older US adults with and without diabetes,”
337 *JAMA Netw. Open*, vol. 4, no. 6, pp. e2112210–e2112210, 2021.
- 338 [17] X. Wang *et al.*, “Aspirin use in patients with diagnosed diabetes in the United States and
339 China: Nationally representative analysis,” *Diabetes Vasc. Dis. Res.*, vol. 18, no. 6, p.
340 14791641211067416, 2021.
- 341 [18] D. B. Rolka, A. Fagot-Campagna, and K. M. V. Narayan, “Aspirin use among adults with
342 diabetes: estimates from the Third National Health and Nutrition Examination Survey,”
343 *Diabetes Care*, vol. 24, no. 2, pp. 197–201, 2001.
- 344 [19] E. Demirci *et al.*, “Appropriateness of aspirin use among diabetic patients in primary
345 prevention of atherosclerotic cardiovascular diseases: an analysis of the ASSOS study,”
346 *Eur. Rev. Med. Pharmacol. Sci.*, vol. 27, pp. 307–314, 2023.
- 347 [20] R. S. Hira *et al.*, “Frequency and practice-level variation in inappropriate aspirin use for
348 the primary prevention of cardiovascular disease: insights from the National
349 Cardiovascular Disease Registry’s Practice Innovation and Clinical Excellence registry,”
350 *J. Am. Coll. Cardiol.*, vol. 65, no. 2, pp. 111–121, 2015.
- 351 [21] P. Sabitha, A. Kamath, and P. M. Adhikari, “Prescription of Aspirin for adults with
352 Diabetes,” *Int. J. Diabetes Dev. Ctries.*, vol. 28, no. 2, p. 51, 2008.
- 353 [22] C. S. Fox *et al.*, “Update on prevention of cardiovascular disease in adults with type 2
354 diabetes mellitus in light of recent evidence: a scientific statement from the American
355 Heart Association and the American Diabetes Association,” *Circulation*, vol. 132, no. 8,
356 pp. 691–718, 2015.
- 357 [23] K. Bibbins-Domingo and U. S. P. S. T. Force*, “Aspirin use for the primary prevention of
358 cardiovascular disease and colorectal cancer: US Preventive Services Task Force
359 recommendation statement,” *Ann. Intern. Med.*, vol. 164, no. 12, pp. 836–845, 2016.
- 360 [24] C. W. O’Brien, S. P. Juraschek, and C. C. Wee, “Prevalence of aspirin use for primary
361 prevention of cardiovascular disease in the United States: results from the 2017 National
362 Health Interview Survey,” *Ann. Intern. Med.*, vol. 171, no. 8, pp. 596–598, 2019.
- 363 [25] A. D. Association, “10. Cardiovascular disease and risk management: Standards of
364 Medical Care in Diabetes—2019,” *Diabetes Care*, vol. 42, no. Supplement_1, pp. S103–
365 S123, 2019.
- 366 [26] D. K. Arnett *et al.*, “2019 ACC/AHA guideline on the primary prevention of
367 cardiovascular disease: a report of the American College of Cardiology/American Heart
368 Association Task Force on Clinical Practice Guidelines,” *Circulation*, vol. 140, no. 11, pp.
369 e596–e646, 2019.
- 370 [27] L. Hansson *et al.*, “Effects of intensive blood-pressure lowering and low-dose aspirin in
371 patients with hypertension: principal results of the Hypertension Optimal Treatment
372 (HOT) randomised trial,” *Lancet*, vol. 351, no. 9118, pp. 1755–1762, 1998.
- 373




Fig 1




Fig 2